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To elucidate the genetic architecture of amyotrophic lateral sclerosis (ALS) and find 261	
associated loci, we assembled a custom imputation reference panel from whole genome-262	
sequenced ALS patients and matched controls (N = 1,861). Through imputation and 263	
mixed-model association analysis in 12,577 cases and 23,475 controls, combined with 264	
2,579 cases and 2,767 controls in an independent replication cohort, we fine mapped a 265	
novel locus on chromosome 21 and identified C21orf2 as an ALS risk gene. In addition, 266	
we identified MOBP and SCFD1 as novel associated risk loci. We established evidence 267	
for ALS being a complex genetic trait with a polygenic architecture. Furthermore, we 268	
estimated the SNP-based heritability at 8.5%, with a distinct and important role for low 269	
frequency (1–10%) variants. This study motivates the interrogation of larger sample 270	
sizes with full genome coverage to identify rare causal variants that underpin ALS risk. 271	
 272	
ALS is a fatal neurodegenerative disease that affects 1 in 400 people, death occurring within 273	
three to five years1. Twin-based studies estimate heritability to be around 65% and 5–10% of 274	
ALS patients have a positive family history1,2. Both are indicative of an important genetic 275	
component in ALS etiology. Following the initial discovery of the C9orf72 locus in GWASs3–276	
5, the identification of the pathogenic hexanucleotide repeat expansion in this locus 277	
revolutionized the field of ALS genetics and biology6,7. The majority of ALS heritability, 278	
however, remains unexplained and only two additional risk loci have been identified robustly 279	
since3,8. 280	
 281	
To discover new genetic risk loci and elucidate the genetic architecture of ALS, we genotyped 282	
7,763 new cases and 4,669 controls and additionally collected genotype data of published 283	
GWAS in ALS. In total, we analyzed 14,791 cases and 26,898 controls from 41 cohorts 284	
(Supplementary Table 1, Supplementary Note). We combined these cohorts based on 285	
genotyping platform and nationality to form 27 case-control strata. In total 12,577 cases and 286	
23,475 controls passed quality control (Online methods, Supplementary Tables 2–5). 287	
 288	
For imputation purposes we obtained high-coverage (~43.7X) whole genome sequencing data 289	
from 1,246 ALS patients and 615 controls from The Netherlands (Online methods, 290	
Supplementary Fig. 1). After quality control, we constructed a reference panel including 291	
18,741,510 single nucleotide variants. Imputing this custom reference panel into Dutch ALS 292	
cases increased imputation accuracy of low-frequency variants (minor allele frequency, MAF 293	
0.5–10%) considerably compared to commonly used reference panels: the 1000 Genomes 294	
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Project phase 1 (1000GP)9 and Genome of The Netherlands (GoNL)10 (Fig. 1a). The 295	
improvement was also observed when imputing into ALS cases from the UK (Fig. 1b). To 296	
benefit from the global diversity of haplotypes, the custom and 1000GP panels were 297	
combined, which further improved imputation. Given these results, we used the merged 298	
reference panel to impute all strata in our study. 299	
 300	
In total we imputed 8,697,640 variants passing quality control in the 27 strata and separately 301	
tested these for association with ALS risk by logistic regression. Results were then included 302	
in an inverse-variance weighted fixed effects meta-analysis, which revealed 4 loci at genome-303	
wide significance (p < 5 × 10–8) (Fig. 2a).  The previously reported C9orf72 (rs3849943)3–5,8, 304	
UNC13A (rs12608932)3,5 and SARM1 (rs35714695)8 loci all reached genome-wide 305	
significance, as did a novel association for a non-synonymous variant in C21orf2 306	
(rs75087725, p = 8.7 × 10–11, Supplementary Tables 6–10). Interestingly, this variant was 307	
present on only 10 haplotypes in the 1000GP reference panel (MAF = 1.3%), compared to 62 308	
haplotypes in our custom reference panel (MAF = 1.7%). As a result, more strata passed 309	
quality control for this variant by passing the allele frequency threshold of 1% 310	
(Supplementary Table 11). This demonstrates the benefit of the merged reference panel with 311	
ALS-specific content, which improved imputation and resulted in a genome-wide significant 312	
association.  313	
 314	
Linear mixed models (LMM) can improve power while controlling for sample structure11, 315	
particularly in our study that included a large number of imperfectly balanced strata. Even 316	
though LMM for ascertained case-control data has a potential small loss of power11, we 317	
judged the advantage of combining all strata while controlling the false positive rate, to be 318	
more important and therefore jointly analyzed all strata in a LMM to identify additional risk 319	
loci. There was no overall inflation of the linear mixed model’s test statistic compared to the 320	
meta-analysis (Supplementary Fig. 2). We observed modest inflation in the QQ-plot (GC = 321	
1.12, 1000 = 1.01, Supplementary Fig. 3). LD score regression yielded an intercept of 1.10 322	
(standard error 7.8 × 10–3). While the LD score regression intercept can indicate residual 323	
population stratification, which is fully corrected for in a LMM, the intercept can also reflect 324	
a distinct genetic architecture where most causal variants are rare, or a non-infinitesimal 325	
architecture12. The linear mixed model identified all four genome-wide significant 326	
associations from the meta-analysis. Furthermore, three additional loci that included the 327	
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MOBP gene on 3p22.1 (rs616147), SCFD1 on 14q12 (rs10139154) and a long non-coding 328	
RNA on 8p23.2 (rs7813314) were associated at genome-wide significance (Fig. 2b, Table 1, 329	
Supplementary Tables 12–14).  Interestingly, the SNPs in the MOBP locus have been 330	
reported in a GWAS on progressive supranuclear palsy (PSP)13 and as a modifier for survival 331	
in frontotemporal dementia (FTD)14. The putative pleiotropic effect of variants within this 332	
locus suggests a shared neurodegenerative pathway between ALS, FTD and PSP. We also 333	
found rs74654358 at 12q14.2 in the TBK1 gene approximating genome-wide significance 334	
(MAF = 4.9%, OR = 1.21 for A allele, p = 6.6 × 10–8). This gene was recently identified as an 335	
ALS risk gene through exome sequencing15,16.  336	
 337	
In the replication phase, we genotyped the newly discovered associated SNPs in nine 338	
independent replication cohorts, totaling 2,579 cases and 2,767 controls. In these cohorts we 339	
replicated the signals for the C21orf2, MOBP and SCFD1 loci, with lower p-values in the 340	
combined analysis than the discovery phase (combined p-value = 3.08 × 10–10, p = 4.19 × 10–341	
10 and p = 3.45 × 10–8 for rs75087725, rs616147 and rs10139154 respectively, Table 1, 342	
Supplementary Fig. 4) 17. The combined signal for rs7813314 was less significant due to an 343	
opposite effect between the discovery and replication phase, indicating non-replication. 344	
Although replication yielded similar effect estimates for rs10139154 compared to the 345	
discovery phase, this was not statistically significant (p = 0.09) in the replication phase alone. 346	
This reflects the limited sample size of our replication phase, which is inherent to the low 347	
prevalence of ALS and warrants even larger sample sizes to replicate this signal robustly.  348	
 349	
There was no evidence for residual association within each locus after conditioning on the top 350	
SNP, indicating that all risk loci are independent signals. Apart from the C9orf72, UNC13A 351	
and SARM1 loci, we found no evidence for associations previously described in smaller 352	
GWAS (Supplementary Table 15). 353	
 354	
The associated low-frequency non-synonymous SNP in C21orf2 suggested that this gene 355	
could directly be involved in ALS risk. Indeed, we found no evidence that linkage 356	
disequilibrium of sequenced variants beyond C21orf2 explained the association within this 357	
locus (Supplementary Fig. 5). In addition, we investigated the burden of rare coding 358	
mutations in a set of whole genome sequenced cases (N = 2,562) and controls (N = 1,138). 359	
After quality control these variants were tested using a pooled association test for rare variants 360	
corrected for population structure (T5 and T1 for 5% and 1% allele frequency, 361	
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Supplementary Note). This revealed an excess of non-synonymous and loss-of-function 362	
mutations in C21orf2 among ALS cases that persists after conditioning on rs75087725 (pT5 = 363	
9.2 × 10–5, pT1 = 0.01, Supplementary Fig. 6), which further supports that C21orf2 364	
contributes to ALS risk. 365	
 366	
In an effort to fine-map the other loci to susceptibility genes, we searched for SNPs in these 367	
loci with cis-eQTL effects observed in brain and other tissues (Supplementary Note, 368	
Supplementary Table 16)18. There was overlap with previously identified brain cis-eQTLs 369	
for five regions (Supplementary Fig. 7, Supplementary Table 17, Supplementary Data 370	
Set 1). Interestingly, within the C9orf72 locus we found that proxies of rs3849943 (LD r2 = 371	
0.21 - 0.56) had a brain cis-eQTL effect on C9orf72 only (minimal p = 5.27 × 10–7), which 372	
harbors the hexanucleotide repeat expansion that drives this GWAS signal. Additionally, we 373	
found that rs12608932 and its proxies within the UNC13A locus had exon-level cis-eQTL 374	
effect on KCNN1 in frontal cortex (p = 1.15 × 10–3)19. Another overlap was observed in the 375	
SARM1 locus where rs35714695 and its proxies had the strongest exon-level cis-eQTL effect 376	
on POLDIP2 in multiple brain tissues (p = 2.32 × 10–3). Within the SCFD1 locus rs10139154 377	
and proxies had a cis-eQTL effect on SCFD1 in cerebellar tissue (p = 7.71 × 10–4). For the 378	
MOBP locus, rs1768208 and proxies had a cis-eQTL effect on RPSA (p = 7.71 × 10–4).  379	
 380	
To describe the genetic architecture of ALS, we calculated polygenic scores that can be used 381	
to predict phenotypes for traits with a polygenic architecture20. We calculated the SNP effects 382	
using a linear mixed model in 18 of the 27 strata and subsequently assessed their predictive 383	
ability in the other 9 independent strata. This revealed that a significant, albeit modest, 384	
proportion of the phenotypic variance could be explained by all SNPs (Nagelkerke r2 = 385	
0.44%, r2 = 0.15% on the liability scale, p = 2.7 × 10–10, Supplementary Fig. 8). This finding 386	
adds to the existing evidence that ALS is a complex genetic trait with a polygenic 387	
architecture. To further quantify the contribution of common SNPs to ALS risk, we estimated 388	
the SNP-based heritability using three approaches, all assuming a population baseline risk of 389	
0.25%21. GCTA-REML estimated the SNP-based heritability at 8.5% (SE 0.5%). Haseman-390	
Elston regression yielded a very similar 7.9% and LD score regression estimated the SNP-391	
based heritability at 8.2% (SE 0.5%). The heritability estimates per chromosome were 392	
strongly correlated with chromosome length (p = 4.9 × 10–4, r2 = 0.46, Fig. 3a), which again is 393	
indicative of the polygenic architecture of ALS. 394	
 395	
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We found that the genome-wide significant loci only explained 0.2% of the heritability and 396	
thus the bulk of the heritability (8.3%, SE 0.3%) was captured in SNPs below genome-wide 397	
significance. This implies that many genetic risk variants have yet to be discovered. 398	
Understanding where these unidentified risk variants remain across the allele frequency 399	
spectrum will inform designing future studies to identify these variants. We, therefore, 400	
estimated heritability partitioned by minor allele frequency. Furthermore, we contrasted this 401	
to common polygenic traits studied in GWASs such as schizophrenia. We observed a clear 402	
trend that indicated that most variance is explained by low-frequency SNPs (Fig. 3b). 403	
Exclusion of the C9orf72 locus, which harbors the rare pathogenic repeat expansion, and the 404	
other genome-wide significant loci did not affect this trend (Supplementary fig. 9). This 405	
architecture is different from that expected for common polygenic traits and reflects a 406	
polygenic rare-variant architecture observed in simulations22.  407	
 408	
To gain better insight into the biological pathways that explain the associated loci found in 409	
this study we looked for enriched pathways using DEPICT23. This revealed SNAP receptor 410	
(SNARE) activity as the only enriched category (FDR < 0.05, Supplementary Fig. 10). 411	
SNARE complexes play a central role in neurotransmitter release and synaptic function24, 412	
which are both perturbed in ALS25.  413	
 414	
Although the biological role of C21orf2, a conserved leucine-rich repeat protein, remains 415	
poorly characterized, it is part of the ciliome and is required for the formation and/or 416	
maintenance of primary cilia26. Defects in primary cilia are associated with various 417	
neurological disorders and cilia numbers are decreased in G93A SOD1 mice, a well-418	
characterized ALS model27. C21orf2 has also been localized to mitochondria in immune 419	
cells28 and is part of the interactome of the protein product of NEK1, which has previously 420	
been associated with ALS15. Both proteins appear to be involved in DNA repair 421	
mechanisms29.	Although future studies are needed to dissect the function of C21orf2 in ALS 422	
pathophysiology it is tempting to speculate that defects in C21orf2 lead to primary cilium 423	
and/or mitochondrial dysfunction or inefficient DNA repair and thereby adult onset disease. 424	
The other associated loci will require more extensive studies to fine-map causal variants. The 425	
SARM1 gene has been suggested as a susceptibility gene for ALS, mainly because of its role 426	
in Wallerian degeneration and interaction with UNC13A8,30. Although these are indeed 427	
interesting observations, the brain cis-eQTL effect on POLDIP2 suggests that POLDIP2 and 428	
not SARM1 could in fact be the causal gene within this locus. Similarly, KCNN1, which 429	
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encodes a neuronal potassium channel involved in neuronal excitability, could be the causal 430	
gene either through a direct eQTL effect or rare variants in LD with the associated SNP in 431	
UNC13A. 432	
 433	
In conclusion, we identified a key role for rare variation in ALS and discovered SNPs in 434	
novel complex loci. Our study therefore informs future study design in ALS genetics: the 435	
combination of larger sample sizes, full genome coverage and targeted genome editing 436	
experiments, leveraged together to fine map novel loci, identify rare causal variants and 437	
thereby elucidate the biology of ALS.438	
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 562	
FIGURE LEGENDS 563	
Figure 1. Imputation accuracy comparison. The aggregate r2 value between imputed and 564	
sequenced genotypes on chromosome 20 using different reference panels for imputation. 565	
Allele frequencies are calculated from the Dutch samples included in the Genome of the 566	
Netherlands cohort. The highest imputation accuracy was achieved when imputing from the 567	
merged custom and 1000GP panels. This difference is most pronounced for low frequency 568	
(0.5–10%) alleles in both ALS cases from The Netherlands (a) and United Kingdom (b). 569	
 570	
Figure 2. Meta-analysis and linear mixed model associations. (a) Manhattan plot for meta-571	
analysis results. This yielded four genome-wide significant associations highlighted with 572	
names indicating the closest gene. The associated SNP in C21orf2 is a non-synonymous 573	
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variant not found in previous GWAS. (b) Manhattan plot for linear mixed model results. This 574	
association analysis yielded three additional loci reaching genome-wide significance (MOBP, 575	
LOC101927815 and SCFD1). SNPs in the previously identified ALS risk gene TBK1 576	
approached genome-wide significance (p = 6.6 × 10–8). Since the C21orf2 SNP was removed 577	
from a Swedish stratum because of a MAF < 1%, this SNP was tested separately, but is 578	
presented here together with all other SNPs with a MAF > 1% in every stratum. Here, 579	
LOC101927815 is colored grey because the association for this locus could not be replicated. 580	
 581	
Figure 3. Partitioned heritability. (a) The heritability estimates per chromosome were 582	
strongly correlated with chromosome length (p = 4.9 × 10–4). (b) For ALS there was a clear 583	
trend where more heritability was explained within the lower allele frequency bins. This 584	
effect was still observed when, for a fair comparison between ALS and a previous study 585	
partitioning heritability for schizophrenia (SCZ) using identical methods22, SNPs present in 586	
HapMap3 (HM3) were included. The pattern for ALS resembles that observed in a rare 587	
variant model simulation performed in this study. Error bars reflect standard errors. 588	
 589	
TABLES 590	
Table 1. Discovery and replication of novel genome-wide significant loci. 591	
 Discovery   Replication   Combined 
SNP MAFcases MAFcontrols OR Pmeta PLMM 
 
MAFcases  MAFcontrols OR P  Pcombined I2 
rs75087725 0.02 0.01 1.45 8.65 × 10–11 2.65 × 10–9 0.02 0.01 1.65 3.89 × 10–3  3.08 × 10–10 0.00* 
rs616147 0.30 0.28 1.10 4.14 × 10–5 1.43 × 10–8  0.31 0.28 1.13 2.35 × 10–3  4.19 × 10–10 0.00* 
rs10139154 0.34 0.31 1.09 1.92 × 10–5 4.95 × 10–8  0.33 0.31 1.06 9.55 × 10–2  3.45 × 10–8 0.05* 
rs7813314 0.09 0.10 0.87 7.46 × 10–7 3.14 × 10–8   0.12 0.10 1.17 7.75 × 10–3  1.05 × 10–5 0.80** 
 592	
Table 1. Discovery and replication of novel genome-wide significant loci. Genome-wide 593	
significant loci from the discovery phase including 12,557 cases and 23,475 controls were 594	
directly genotyped and tested for association in the replication phase including 2,579 cases 595	
and 2,767 controls. The three top associated SNPs in the MOBP (rs616147), SCFD1 596	
(rs10139154) and C21orf2 (rs75087725) loci replicated with associations in identical 597	
directions as in the discovery phase and an association in the combined analysis that exceeded 598	
the discovery phase. * Cochrane’s Q test: p > 0.1, ** Cochrane’s Q test: p = 4.0 × 10–6, Chr = 599	
chromosome; SNP = single nucleotide polymorphism, MAF = minor allele frequency, OR = 600	
odds ratio, Pmeta = meta-analysis p-value, PLMM = linear mixed model p-value, Pcombined = meta-601	
analysis of discovery linear mixed model and associations from replication phase. 602	
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 603	
ONLINE METHODS 604	
Software packages used, their version, web source, and references are described in the 605	
Supplementary Table 18. 606	
 607	
GWAS discovery phase and quality control. Details on the acquired genotype data from 608	
previously published GWAS are described in Supplementary Table 1. Methods for case and 609	
control ascertainment for each cohort are described in the Supplementary Note. All cases 610	
and controls gave written informed consent and the relevant institutional review boards 611	
approved this study. To obtain genotype data for newly genotyped individuals, genomic DNA 612	
was hybridized to the Illumina OmniExpress array according to manufacturer’s protocol. 613	
Subsequent quality control included: 614	
1) Removing low quality SNPs and individuals from each cohort. 615	
2) Combining unbalanced cohorts based on nationality and genotyping platform to form 616	
case-control strata. 617	
3) Removing low quality SNPs, related individuals and population outliers per stratum.  618	
4) Calculate genomic inflation factors per stratum. 619	
More details are described in the Supplementary Note and Supplementary Fig. 11. The 620	
number of SNPs and individuals failing each QC step per cohort and stratum are displayed in 621	
Supplementary Tables 2–5. 622	
 623	
Whole genome sequencing (custom reference panel). Individuals were whole genome 624	
sequenced on the Illumina HiSeq 2500 platform using PCR free library preparation and 100bp 625	
paired-end sequencing yielding a minimum 35X coverage. Reads were aligned to the hg19 626	
human genome build and after variant calling (Isaac variant caller) additional SNV and 627	
sample quality control was performed (Supplementary Note and Supplementary Fig. 12). 628	
Individuals in our custom reference panel were also included in the GWAS in strata sNL2, 629	
sNL3 and sNL4. 630	
 631	
Merging reference panels. All high quality calls in the custom reference panel were phased 632	
using SHAPEIT2 software. After checking strand and allele inconsistencies, both the 1000 633	
Genomes Project (1000GP) reference panel (release 05-21-2011)31 and custom reference 634	
panel were imputed up to the union of their variants as described previously32. Those variants 635	
with inconsistent allele frequencies between the two panels were removed. 636	
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 637	
Imputation accuracy performance. To assess the imputation accuracy between different 638	
reference panels, 109 unrelated ALS cases of Dutch ancestry sequenced by Complete 639	
Genomics and 67 ALS cases from the UK sequenced by Illumina were selected as a test 640	
panel. All variants not present on the Illumina Omni1M array were masked and the SNVs on 641	
chromosome 20 were subsequently imputed back using four different reference panels 642	
(1000GP, GoNL, custom panel and merged panel). Concordance between the imputed alleles 643	
and sequenced alleles was assessed within each allele frequency bin where allele frequencies 644	
are calculated from the Dutch samples included in the Genome of the Netherlands cohort. 645	
 646	
GWAS imputation. Pre-phasing was performed per stratum using SHAPEIT2 with the 647	
1000GP phase 1 (release 05-21-2011) haplotypes31 as a reference panel. Subsequently, strata 648	
were imputed up to the merged reference panel in 5 megabase chunks using IMPUTE2. 649	
Imputed variants with a MAF < 1% or INFO score < 0.3 were excluded from further analysis. 650	
Variants with allele frequency differences between strata, defined as deviating > 10SD from 651	
the normalized mean allele frequency difference between those strata and an absolute 652	
difference > 5%, were excluded, since they are likely to represent sequencing or genotyping 653	
artifacts. Imputation concordance scores for cases and controls were compared to assess 654	
biases in imputation accuracy (Supplementary Table 19). 655	
 656	
Meta-analysis. Logistic regression was performed on imputed genotype dosages under an 657	
additive model using SNPTEST software. Based on scree plots, 1 to 4 principal components 658	
were included per stratum. These results were then combined in an inverse-variance weighted 659	
fixed effect meta-analysis using METAL. No marked heterogeneity across strata was 660	
observed as the Cochrane’s Q test statistics did not deviate from the null-distribution ( = 661	
0.96). Therefore, no SNPs were removed due to excessive heterogeneity. The genomic 662	
inflation factor was calculated and the quantile-quantile plot is provided in Supplementary 663	
Fig. 3a.  664	
 665	
Linear mixed model. All strata were combined including SNPs that passed quality control in 666	
every stratum. Subsequently the genetic relationship matrices (GRM) were calculated per 667	
chromosome including all SNPs using the Genome­Wide Complex Trait Analysis (GCTA) 668	
software package. Each SNP was then tested in a linear mixed model including a GRM 669	
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composed of all chromosomes excluding the target chromosome (leave one chromosome out, 670	
LOCO). The genomic inflation factor was calculated and the quantile-quantile plot is 671	
provided as Supplementary Fig. 3b. 672	
 673	
Replication. For the replication phase independent ALS cases and controls from Australia, 674	
Belgium, France, Germany, Ireland, Italy, The Netherlands and Turkey that were not used in 675	
the discovery phase were included. A pre-designed TaqMan genotyping assay was used to 676	
replicate rs75087725 and rs616147. Sanger sequencing was performed to replicate 677	
rs10139154 and rs7813314 (Supplementary Note and Supplementary Table 20). All 678	
genotypes were tested in a logistic regression per country and subsequently meta-analyzed. 679	
 680	
Rare variant analysis in C21orf2. The burden of non-synonymous rare variants in C21orf2 681	
was assessed in whole genome sequencing data obtained from ALS cases and controls from 682	
The Netherlands, Belgium, Ireland, United Kingdom and the United States. After quality 683	
control the burden of non-synonymous and loss-of-function mutations in C21orf2 were tested 684	
for association per country and subsequently meta-analyzed. More details are provided in the 685	
Supplementary Note and Supplementary Fig. 13. 686	
 687	
Polygenic risk scores. To assess the predictive accuracy of polygenic risk scores in an 688	
independent dataset SNP weights were assigned based on the linear mixed model (GCTA-689	
LOCO) analysis in 18/27 strata. SNPs in high LD (r2 > 0.5) within a 250 kb window were 690	
clumped. Subsequently, polygenic risk scores for cases and controls in the 9 independent 691	
strata were calculated based on their genotype dosages using PLINK v1.9. To obtain the 692	
Nagelkerke R2 and corresponding p-values these scores were then regressed on their true 693	
phenotype in a logistic regression where (based on scree plots) the first three PCs, sex and 694	
stratum were included as covariates. 695	
 696	
SNP-based heritability estimates. GCTA-REML. GRMs were calculated using GCTA 697	
software including genotype dosages passing quality control in all strata. Based on the 698	
diagonal of the GRM individuals representing subpopulations that contain an abundance of 699	
rare alleles (diagonal values mean +/- 2SD) were removed (Supplementary Fig. 14a). Pairs 700	
where relatedness (off-diagonal) exceeded 0.05 were removed as well (Supplementary Fig. 701	
14b). The eigenvectors for the first 10 PCs were included as fixed effects to account for more 702	
subtle population structure. The prevalence of ALS was defined as the life-time morbid risk 703	
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for ALS (i.e. 1/400)19. To estimate the SNP-based heritability for all non-genome-wide 704	
significant SNPs, genotypes for the SNPs reaching genome-wide significance were modeled 705	
as fixed effect. The variance explained by the GRM therefore reflects the SNP-based 706	
heritability of all non-genome-wide significant SNPs. SNP-based heritability partitioned by 707	
chromosome or MAF was calculated by including multiple GRMs, calculated on SNPs from 708	
each chromosome or within the respective frequency bin, in one model.  709	
Haseman-Elston regression. The Phenotype correlation - Genotype correlation (PCGC) 710	
regression software package was used to calculate heritability based on the Haseman-Elston 711	
regression including the eigenvectors for the first 10 PCs as covariates. The prevalence was 712	
again defined as the life-time morbid risk (1/400).  713	
LD score regression. Summary statistics from GCTA-LOCO and LD scores calculated from 714	
European individuals in 1000GP were used for LD score regression. Strongly associated 715	
SNPs (p < 5 × 10-8) and variants not in HapMap3 were excluded. Considering adequate 716	
correction for population structure and distant relatedness in the linear mixed model, the 717	
intercept was constrained to 1.012. 718	
Biological pathway analysis (DEPICT). Functional interpretation of associated GWAS loci 719	
was carried out using DEPICT, using locus definition based on 1000GP phase 1 data. This 720	
method prioritizes genes in the affected loci, predicts involved pathways, biological processes 721	
and tissues, using gene co-regulation data from 77,840 expression arrays. Three separate 722	
analyses were performed for GWAS loci reaching p = 10–4, p = 10–5 or p = 10–6. One thousand 723	
permutations were used for adjusting the nominal enrichment p-values for biases and 724	
additionally 200 permutations were used for FDR calculation. 725	
 726	
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